Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541

Purpose. This study was performed to find which types of hepatic CYP isoforms are responsible for the metabolism of mirodenafil (a new erectogenic) and one of its metabolite, SK3541, using various hepatic CYP inducers and inhibitors in rats. Methods. Mirodenafil at a dose of 20 mg/kg was administere...

Full description

Bibliographic Details
Main Authors: Young Hee Choi, Young Sun Lee, Myung Gull Lee, Tae Kon Kim, Bong-Yong Lee
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2010-04-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6681
id doaj-432b24f1cdf9460f896282d90d4f593c
record_format Article
spelling doaj-432b24f1cdf9460f896282d90d4f593c2020-11-25T03:37:18ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262010-04-0113110.18433/J3688MPharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541Young Hee Choi0Young Sun Lee1Myung Gull Lee2Tae Kon Kim3Bong-Yong Lee4Seoul National UniversitySeoul National UniversitySeoul National UniversitySK ChemicalsSK ChemicalsPurpose. This study was performed to find which types of hepatic CYP isoforms are responsible for the metabolism of mirodenafil (a new erectogenic) and one of its metabolite, SK3541, using various hepatic CYP inducers and inhibitors in rats. Methods. Mirodenafil at a dose of 20 mg/kg was administered intravenously to control rats and rats pretreated with various CYP inducers and inhibitors. The disappearance of SK3541 was also measured in vitro hepatic microsomes of rats with and without CYP inducer and inhibitors. Results. Compared to controls, in rats pretreated with 3-methylcholanthrene, orphenadrine, and dexamethasone (main inducers of CYP1A1/2, 2B1/2, and 3A1/2, respectively), the non-renal clearances (CLNRs) of mirodenafil were significantly faster (by 39.4%, 59.3%, and 63.9%, respectively). However, compared to controls, in rats pretreated with quinine and troleandomycin (main inhibitors of CYP2D subfamily and 3A1/2, respectively), the CLNRs of mirodenafil were significantly slower (by 36.1% and 33.2%, respectively). In rat hepatic microsomes spiked with furafylline, quinine, and troleandomycin (main inhibitors of CYP1A2, 2D subfamily, and 3A1/2, respectively), the intrinsic clearances (CLints) for the disappearance of SK3541 were significantly slower (by 18.4%, 35.3%, and 51.5%, respectively) than controls. Also in rat hepatic microsomes pretreated with orphenadrine (a main inducer of CYP2B1/2), the CLint for the disappearance of SK3541 was significantly faster (by 55.5%) than controls. Conclusions. The above data suggest that hepatic CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 are involved in the metabolism of both mirodenafil and SK3541 in rats.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6681
collection DOAJ
language English
format Article
sources DOAJ
author Young Hee Choi
Young Sun Lee
Myung Gull Lee
Tae Kon Kim
Bong-Yong Lee
spellingShingle Young Hee Choi
Young Sun Lee
Myung Gull Lee
Tae Kon Kim
Bong-Yong Lee
Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
Journal of Pharmacy & Pharmaceutical Sciences
author_facet Young Hee Choi
Young Sun Lee
Myung Gull Lee
Tae Kon Kim
Bong-Yong Lee
author_sort Young Hee Choi
title Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
title_short Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
title_full Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
title_fullStr Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
title_full_unstemmed Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541
title_sort pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, sk3541, in rats: involvement of cyp1a1/2, 2b1/2, 2d subfamily, and 3a1/2 for the metabolism of both mirodenafil and sk3541
publisher Canadian Society for Pharmaceutical Sciences
series Journal of Pharmacy & Pharmaceutical Sciences
issn 1482-1826
publishDate 2010-04-01
description Purpose. This study was performed to find which types of hepatic CYP isoforms are responsible for the metabolism of mirodenafil (a new erectogenic) and one of its metabolite, SK3541, using various hepatic CYP inducers and inhibitors in rats. Methods. Mirodenafil at a dose of 20 mg/kg was administered intravenously to control rats and rats pretreated with various CYP inducers and inhibitors. The disappearance of SK3541 was also measured in vitro hepatic microsomes of rats with and without CYP inducer and inhibitors. Results. Compared to controls, in rats pretreated with 3-methylcholanthrene, orphenadrine, and dexamethasone (main inducers of CYP1A1/2, 2B1/2, and 3A1/2, respectively), the non-renal clearances (CLNRs) of mirodenafil were significantly faster (by 39.4%, 59.3%, and 63.9%, respectively). However, compared to controls, in rats pretreated with quinine and troleandomycin (main inhibitors of CYP2D subfamily and 3A1/2, respectively), the CLNRs of mirodenafil were significantly slower (by 36.1% and 33.2%, respectively). In rat hepatic microsomes spiked with furafylline, quinine, and troleandomycin (main inhibitors of CYP1A2, 2D subfamily, and 3A1/2, respectively), the intrinsic clearances (CLints) for the disappearance of SK3541 were significantly slower (by 18.4%, 35.3%, and 51.5%, respectively) than controls. Also in rat hepatic microsomes pretreated with orphenadrine (a main inducer of CYP2B1/2), the CLint for the disappearance of SK3541 was significantly faster (by 55.5%) than controls. Conclusions. The above data suggest that hepatic CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 are involved in the metabolism of both mirodenafil and SK3541 in rats.
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6681
work_keys_str_mv AT youngheechoi pharmacokineticsofmirodenafilanewerectogenicanditsmetabolitesk3541inratsinvolvementofcyp1a122b122dsubfamilyand3a12forthemetabolismofbothmirodenafilandsk3541
AT youngsunlee pharmacokineticsofmirodenafilanewerectogenicanditsmetabolitesk3541inratsinvolvementofcyp1a122b122dsubfamilyand3a12forthemetabolismofbothmirodenafilandsk3541
AT myunggulllee pharmacokineticsofmirodenafilanewerectogenicanditsmetabolitesk3541inratsinvolvementofcyp1a122b122dsubfamilyand3a12forthemetabolismofbothmirodenafilandsk3541
AT taekonkim pharmacokineticsofmirodenafilanewerectogenicanditsmetabolitesk3541inratsinvolvementofcyp1a122b122dsubfamilyand3a12forthemetabolismofbothmirodenafilandsk3541
AT bongyonglee pharmacokineticsofmirodenafilanewerectogenicanditsmetabolitesk3541inratsinvolvementofcyp1a122b122dsubfamilyand3a12forthemetabolismofbothmirodenafilandsk3541
_version_ 1724545886205247488